Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606346 · ClinicalTrials.gov registry record
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A clinical trial of Ulcerative Colitis and Crohn's Disease, sponsored by Janssen Biotech.
- Active
- Registry status
- 4,970
- Enrollment target
- 20
- Study locations
NCT00606346 is a study of Ulcerative Colitis and Crohn's Disease that is active but no longer recruiting, run by Janssen Biotech. The registered enrollment target is 4,970 participants, above the 2,017-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (146% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT00606346, a study of Ulcerative Colitis and Crohn's Disease, is active but no longer recruiting, sponsored by Janssen Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- 4,970 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD). Particular attention will be directed to recording safety outcomes reported in association with infliximab and other prescribed IBD therapies. In addition, information on disease status and quality of life will be collected.
Conditions Studied
Interventions
- BIOLOGICAL Anti TNF therapy including infliximab
- DRUG No Biologics
Study Locations (20)
California
- - Los Angeles
- - Oakland
- - Sacramento
- - San Diego
- - San Francisco
Florida
- - Gainesville
- - Miami
- - Orlando
Connecticut
- - Hartford
- - New Haven
Alabama
- - Mobile
Arizona
- - Phoenix
Colorado
- - Aurora
Georgia
- - Atlanta
Idaho
- - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,970 participants |
| Start Date | 2007-05-31 |
| Est. Completion | 2038-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606346
The ClinicalTrials.gov registry entry for NCT00606346 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 4,970 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,017-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (146% higher). The listed sponsor is Janssen Biotech, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Anti TNF therapy including infliximab is the first listed.
NCT00606346 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00606346 about?
NCT00606346 is a clinical study titled "A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease". The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD). Particular attention will be directed to recording safety outcomes reported in association with infliximab and other prescribed IBD therapies. In addition, i...
What is the current status of trial NCT00606346?
This trial is currently active not recruiting. The enrollment target is 4,970 participants. The study started on 2007-05-31. Estimated completion is 2038-06-30.
What conditions does trial NCT00606346 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Diseases, Indeterminate Colitis.
What interventions are being tested in trial NCT00606346?
The interventions under investigation include: Anti TNF therapy including infliximab (BIOLOGICAL), No Biologics (DRUG).
Who is sponsoring clinical trial NCT00606346?
This trial is sponsored by Janssen Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606346 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.